Implanting 1.1B4 human β-cell pseudoislets improves glycaemic control in diabetic severe combined immune deficient mice

Figure 3 Insulin content (A) of excised 1. 1B4 cell/pseudoislet cell masses and the effects of implantation on plasma insulin (B), pancreatic insulin content (C), plasma glucagon (D) and pancreatic glucagon content (E) of normal and streptozotocin diabetic severe combined immunodeficient mice. Values are mean ± SEM (n = 4). ^aP < 0.05, ^dP < 0.01, ^eP < 0.01 vs diabetic control animals.